Transthyretin Amyloidosis with Cardiomyopathy

• CLINICAL_TRIALS trial_result · 2026-08-25
  Clinical Trial Update: CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) [Phase 3]

  Phase 3 study of eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) has completed.

• CLINICAL_TRIALS research · 2026-04-24
  Clinical Trial Update: DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

  DemonsTTRate is a global, observational, multicenter study to collect long-term real-world data on patients with transthyretin amyloidosis w…

• CLINICAL_TRIALS research · 2026-04-17
  Clinical Trial Update: TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [Phase 3]

  Phase 3 study TRITON-CM is evaluating Nucresiran in patients with transthyretin amyloidosis with cardiomyopathy, and the trial is currently …

• CLINICAL_TRIALS research · 2026-03-27
  Clinical Trial Update: MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) [Phase 3]

  Phase 3 trial MAGNITUDE evaluating NTLA-2001 in transthyretin amyloidosis with cardiomyopathy is currently recruiting.

• CLINICAL_TRIALS trial_result · 2026-02-20
  Clinical Trial Update: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [Phase 3]

  A Phase 3 clinical trial evaluating vutrisiran for transthyretin amyloidosis with cardiomyopathy is currently enrolling by invitation.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-10-21
  Clinical Trial Update: HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [Phase 3]

  This clinical trial update reports on the Phase 3 HELIOS-B study evaluating vutrisiran for transthyretin amyloidosis with cardiomyopathy; re…

• CLINICAL_TRIALS research · 2025-08-11
  Clinical Trial Update: To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) [Phase 3]

  This Phase 3 clinical trial update describes evaluating long-term safety and tolerability of acoramidis in newly diagnosed transthyretin amy…

• CLINICAL_TRIALS research · 2025-06-27
  Clinical Trial Update: Quantitative-imaging in Cardiac Transthyretin Amyloidosis

  A clinical trial update from the University of Edinburgh about quantitative imaging in transthyretin amyloidosis with cardiomyopathy (ATTR-C…

• CLINICAL_TRIALS research · 2025-02-19
  Clinical Trial Update: A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.

  A multicenter study update evaluating how atrioventricular regurgitation is defined, how common it is, and its prognostic impact in patients…

• CLINICAL_TRIALS trial_result · 2023-10-18
  Clinical Trial Update: APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) [Phase 3]

  APOLLO-B is a Phase 3 trial evaluating patisiran in transthyretin amyloidosis with cardiomyopathy. The study has completed, and results were…

• FDA approval · 2023-10-17
  FDA Approved: VYNDAMAX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  The FDA approved a supplemental application for VYNDAMAX (tafamidis) from Pfizer Laboratories Div Pfizer Inc, typically to support labeling …

• FDA approval · 2019-05-03
  FDA Approved: VYNDAMAX — Original Application (Pfizer Laboratories Div Pfizer Inc)

  FDA approved the original application for VYNDAMAX (TAFAMIDIS) from Pfizer Laboratories Div Pfizer Inc for the treatment of transthyretin am…